Medicis Pharmaceutical Corp

• Dermatology Market Movers Create New Investment Opportunities

  By Jordo Bivona - December 14, 2012 | Tickers: AGN, MRX, VRX

  Valeant (NYSE: VRX) is one step closer to acquiring Medicis (NYSE: MRX) with the U.S. Federal Trade Commission granting the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976. Valeant had announced its intention to acquire the specialty pharmaceutical company in September 2012, and the deal is expected to be worth approximately $2.6 billion. Medicis is engaged in the development and marketing of more »

• This Hedge Fund's Picks Have Returned 20% Two Straight Quarters

  By Meena Krishnamsetty - November 6, 2012 | Tickers: AUXL, CYBX, MRX, ONXX, VPHM

  We track over 400 funds and investors, and have calculated the value-weighted returns for all funds in the 1500 largest stocks, while compiling a list of the top performing funds for the first three quarters of 2012. The returns are based on the fund’s 13F long positions only, as we do not have access to their short positions.

  Palo Alto has done it again, finishing in the top five more »

• Aspire to Beauty=Make More Money

  By AnnaLisa Kraft - October 10, 2012 | Tickers: AGN, MRX, REGN, TEVA, VRX

  Maybe you remember a commercial slogan, “Don’t hate me because I’m beautiful.” Far from it, beautiful (or handsome) people make more money over the course of a lifetime as people throw opportunities and money at them. OK, maybe now you hate them. But an infographic on trendhunter.com claims a beautiful woman can earn 4% more over the course of a lifetime than average looking women with a more »

• Valeant Deal May Create Leader in US Dermatology Market

  By Tony Daltorio - September 6, 2012 | Tickers: AGN, GSK, MRX, VRX

  As detailed in another article, the wave of mergers and acquisitions in the healthcare sector in recent months continues unabated. The latest deal announced was the $2.6 billion offer made by Valeant Pharmaceuticals International (NYSE: VRX) for Medicis Pharmaceutical (NYSE: MRX). Medicis' best-known products include Solodyn along with Restylane and Dysport, which all compete directly with anti-wrinkle products such as Juvederm and Botox from Allergan (NYSE: AGN). 

  Valeant, which more »

• Buy Yourself Something Pretty

  By AnnaLisa Kraft - July 14, 2012 | Tickers: AGN, AVP, MRX, OMPI

  So I’m writing this in hopes that Obagi Medical Products, Inc. (NASDAQ: OMPI) doesn’t get bought out over the weekend and there’s still some upside. I put off writing it because I hoped to get in but now I find it’s gotten away from me. With management filing an 8K lifting "poison pill" restrictions earlier this week it’s been ramping on chatter of an imminent more »

• J.P. Morgan Healthcare Conference Schedule: Day One

  By Brandy Betz - January 8, 2012 | Tickers: ARAY, ACOR, A, ALGN, AMRN, AMGN, AMLN, ARTC, BIIB, BMRN, BRKR, CFN, CTRX, CELG, CNC, COV, DNDN, XRAY, EW, ENDP, EPOC, ESRX, GHDX, GILD, HLS, HTWR, HMSY, HGSI, IDXX, IPXL, INCY, IRWD, MCK, MRX, MDT, MR, MOH, MYL, NVS, ONXX, PRX, PRGO, QSII, REGN, RMD, RIGL, SGEN, ST, SIAL, THC, MDCO, THOR, VRTX, VVUS, WAT, WMGI, ZLTQ

  The 30th Annual J.P. Morgan Healthcare Conference kicks off with a full day of presentations from companies that range from global pharmaceutical leaders to small cap novel pharmaceutical developers and health technology manufacturers. The majority of the presentations will be available through live webcasts with archived replay offered later in the day.

  I will be following (and covering) the novel therapeutic companies that have caught my eye. VIVUS (NASDAQ: VVUSmore »)